OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Bowman on Rationale for Radio-Labeled Atezolizumab PET/CT Scans in RCC

December 10th 2019

I. Alex Bowman, MD, discusses the rationale for an exploratory clinical trial of radio-labeled 89Zr-atezolizumab PET/CT scans in renal cell carcinoma.

Dr. Perales on the Future of CAR T-Cell Therapy in DLBCL and Follicular Lymphoma

December 10th 2019

Miguel-Angel Perales, MD, discusses the future of CAR T-cell therapy in diffuse large B-cell lymphoma and follicular lymphoma.

Dr. Smith on the Rationale Behind the Fixed Duration Trial for Ibrutinib/Venetoclax in CLL

December 10th 2019

Mitchell R. Smith, MD, PhD, discusses the rationale behind the trial looking at the fixed duration of the ibrutinib and venetoclax combination in chronic lymphocytic leukemia.

Dr. Benson on MSI Testing in Colorectal Cancer

December 10th 2019

Al B. Benson, MD, discusses the implications of microsatellite instability testing on patients with colorectal cancer.

Dr. Vaishampayan on Immunotherapy in mRCC

December 10th 2019

Ulka Vaishampayan, MD, discusses the utility of immunotherapy in metastatic renal cell carcinoma.

Dr. Rizk on Eligibility Criteria for Surgical Resection in Lung Cancer

December 10th 2019

Nabil P. Rizk, MD, MS, MPH, discusses criteria for surgical resection in lung cancer.

Dr. Ilson Discusses Challenges with Immunotherapy in Gastric Cancer

December 10th 2019

David H. Ilson, MD, PhD, discusses remaining challenges with immunotherapy in gastric cancer.

Dr. Catenacci on Treatment Selection in Esophagogastric Junction Adenocarcinoma

December 7th 2019

Daniel Catenacci, MD, discusses factors that may guide treatment selection for patients with esophagogastric junction adenocarcinoma.

Dr. Moses on Recent Trials in mHSPC

December 7th 2019

Kelvin Alexander Moses, MD, PhD, discusses recent trials in metastatic hormone-sensitive prostate cancer.

Dr. Oh on Remaining Challenges in mHSPC

December 7th 2019

William K. Oh, MD, discusses remaining challenges in metastatic hormone-sensitive prostate cancer.

Dr. Grande on the Rationale of the IMvigor130 Trial in Urothelial Cancer

December 7th 2019

Enrique Grande, MD, discusses the rationale of the IMvigor130 trial in urothelial cancer.

Dr. Rule on Potential for CAR T-Cell Therapy in MCL

December 7th 2019

Simon Rule, MD, discusses the potential for CAR T-cell therapy in treating patients with mantle cell lymphoma.

Dr. Gerson on Updates in Relapsed/Refractory MCL

December 6th 2019

James N. Gerson, MD, discusses recent updates in relapsed/refractory mantle cell lymphoma.

Dr. Shah on Improving the Benefit of Immunotherapy in Gastric/GEJ Cancer

December 6th 2019

Manish A. Shah, MD, discusses ongoing efforts to improve immunotherapy in gastric and gastroesophageal junction cancer.

Dr. Voss on Phase I/II Trial Data of MEDI0680/Durvalumab Versus Nivolumab in mRCC

December 6th 2019

Martin H. Voss, MD, discusses results of a randomized phase I/II trial looking at the combination of MEDI0680 and durvalumab (Imfinzi) versus nivolumab (Opdivo) in metastatic renal cell carcinoma.

Next Steps for Wnt Research in Colorectal Cancer

December 6th 2019

Luke Dow, PhD, discusses the next steps for researching the Wnt pathway in colorectal cancer.

Dr. Wierda on Chemoimmunotherapy in CLL

December 6th 2019

William G. Wierda, MD, PhD, discusses the use of chemoimmunotherapy in treating patients with chronic lymphocytic leukemia.

Dr. Hidalgo Medina on Treatment Considerations in Pancreatic Cancer

December 5th 2019

Manuel Hidalgo Medina, MD, PhD, discusses treatment considerations in pancreatic cancer.

Dr. Singh on Potential Implications of the IMvigor130 Trial in Bladder Cancer

December 5th 2019

Parminder Singh, MD, discusses potential implications of the phase III IMvigor130 trial in advanced bladder cancer.

Dr. Corcoran on Promising Combination Strategies With Immunotherapy in mCRC

December 5th 2019

Ryan B. Corcoran, MD, PhD, discusses promising combination strategies with immunotherapy in metastatic colorectal cancer.